Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients. (AI)
Thoracic malignancy is the most commonly diagnosed cancer worldwide.1,2 The incidence of thoracic malignancy has decreased in North America, but not in Asia, where it continues to show an increasing trend. A notable manifestation of the bimodal age distribution of thoracic malignancy has been observed in women. The occurrence of early-onset thoracic malignancy in the Asian population is earlier than that in the Western population, resulting in a higher incidence of thoracic malignancy in young Asian women. Moreover, the late onset age distribution of patients with thoracic malignancy in Asia (40-50 years) is earlier than that in Western countries (60-70 years), peaking at the age of 45-50 years in most women. The age-specific incidence rates of thoracic malignancy increase sharply until the menopausal stage.
Cardiovascular morbidity is higher among women with thoracic malignancy involving the thorax who had received radiotherapy (RT) compared with those not involving the thorax but receiving the same treatment. Thus far, the risks and time to onset of cardiac complications have been unclear in both young and old women. The proportion of young women with thoracic malignancy is higher in Asia than in Western countries. Furthermore, whether Asian women with thoracic malignancy are susceptible to RT remains unclear.
Anthracyclines are important therapeutic agents for breast cancer. Anthracycline-based regimens have similar or improved outcomes relative to the standard treatment regimen of cyclophosphamide, methotrexate, and fluorouracil. However, cardiotoxicity is a long-term toxicity associated with these regimens. The combined use of adjuvant anthracycline-based chemotherapy (CT) and RT may result in high cardiotoxicity. Nonetheless, no clear information on the effects of this combined therapy on the time to onset of both cardiac complications and cardiotoxicity is available. Furthermore, whether the cardiotoxicity of adjuvant RT and anthracycline-based CT is associated with age and ethnicity in women with thoracic malignancy remains unclear.
Therefore, cardiovascular disease is undoubtedly one of the most challenging health problems in the world. More efforts are needed to prevent and better control of this disease. Our proposed monitoring program is to use AI to monitor the basal value variation of personalized cardiovascular disease in cancer patients before and after chemoradiation. In the first year, our team focused on cardiotoxicity associated with cardiovascular disease models and cancer treatments. In the second year, we will apply knowledge in a clinical setting and calculate the severity of cardiac toxicity and its incidence and time response after cancer treatment. In the third year, high-risk groups will be identified to provide preventive intervention to reduce the risk of cancer-treatment related cardiotoxicity.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study is open, prospective study, multi-center, randomized controlled trial, unobtrusive research. This study is start on June 1 2021. And will include 400 patients who have just cardiotoxicity of adjuvant RT and anthracycline-based CT patients who diagnosis of Thoracic malignancy. And random allocation 200 experimental group (Non-invasive Wearable Device) and 200 control group (routine medical).
Ask whether the patients who meet the exclusion criteria are willing to participate in the screening (Screening), if they are willing to join and sign the consent of the subject, and after the patient's condition is stable, conduct an electrocardiogram (V0) before discharge from the hospital. On day 7 (±2 weeks), day 84 (±4 weeks), 168 days (±4 weeks), 252 days (±4 weeks), 336 days (±8 weeks) during routine clinical referral (V1-V5) Both are done once. The results of these two tests and other basic information of the patient, including Demography, Vital Signs, High, Weight, Medication, and European and Taiwan Cardiology Association recommended routine test results of high-risk patients, including Blood Chemistry Panel, NT-proBNP, Echocardiography, Myocardial Perfusion Scan, etc., will record the information of the logged-in subjects on the paper case report form. The CRF only displays the study number, and no subject is available. In addition to the examination of each return visit, the subjects also took the ECG bracelet home at the time of discharge (V0) and wore it every day. After the discharge, the ECG was measured every morning and evening, and their personal activity and sleep were collected. Relevant information. After the subject was discharged from the hospital, the subject tracked the date of all adverse events due to cardiovascular disease within one year, including: heart failure, restenosis due to blood vessel, and non-fatal myocardial infarction , To do blood vessel-related surgery again, and data on the occurrence of death.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: YU ANN FANG, MS
- Numéro de téléphone: 8891 886-2-22490088
- E-mail: runawayyu@hotmail.com
Sauvegarde des contacts de l'étude
- Nom: Ju-Chi Liu, PHD, MD
- Numéro de téléphone: 8170 886-2-22490088
- E-mail: liumdcv@tmu.edu.tw
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- ≥ 20-year-old
- Patients who had received radiotherapy (RT) or anthracycline-based CT or cancer immunotherapy or Targeted Therapy
- Diagnosis of Thoracic malignancy or breast cancer.
- Willing to sign the consent form of the subject and cooperate with the return visit
- Those who are admitted to the hospital and enter the general ward can receive the first ECG heart sound examination
Exclusion Criteria:
- <20-year-old
- Can't received radiotherapy (RT) or anthracycline-based CT or cancer immunotherapy or Targeted Therapy
- Those who cannot perform the first examination after being admitted to the hospital and entering the general ward
- It is impossible to measure the group of ECG and heart sounds. For example, when using Pacemaker, the ECG showed ventricular tachycardia (VT) and Dextrocardia on admission.
- Patients who are bedridden and have difficulty in cooperating with return visits
- Any subject that the physician believes is at high risk for future uncooperative tracking
- Direct participants in this program
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Interventions
Device: Wisdom bracelet Other Names: control group (routine medical) |
Wisdom bracelet
|
|
control
routine medical Non-invasive Wearable Device
|
Wisdom bracelet
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
décès
Délai: Dans l'année
|
la mort, divisée en oui ou non
|
Dans l'année
|
|
insuffisance cardiaque
Délai: Dans l'année
|
Revenir à l'hôpital pour insuffisance cardiaque (jugé par le médecin) après la sortie, divisé en oui ou non
|
Dans l'année
|
|
Acute Coronary Syndrome, Coronary Artery Disease
Délai: Within a year
|
Come back to the hospital for Acute Coronary Syndrome, Coronary Artery Disease (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
|
Myocarditis
Délai: Within a year
|
Come back to the hospital for Myocarditis (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Le médecin ajuste la médecine
Délai: Dans l'année
|
Selon l'ordonnance de médicament délivrée par le médecin, s'il y a un ajustement du médicament, faites un enregistrement, divisé en oui ou non
|
Dans l'année
|
|
Le médecin organise l'examen tôt
Délai: Dans l'année
|
Si le médecin a prévu de faire une échographie cardiaque ou une scintigraphie de perfusion myocardique d'effort et de redistribution avec SPECT Pendant la période sans table, divisée en oui ou non
|
Dans l'année
|
|
Conformité
Délai: Dans l'année
|
Jugé par le médecin, lorsque le patient revient en consultation, le patient est interrogé sur l'observance du médicament dans le passé, divisé en oui ou non
|
Dans l'année
|
|
Frais médicaux
Délai: Dans l'année
|
La somme de toutes les dépenses médicales et d'assurance maladie du patient au cours de l'année écoulée
|
Dans l'année
|
|
Arrhythmia
Délai: Within a year
|
Re-hospitalization for Arrhythmia (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
|
Valvular Heart Disease
Délai: Within a year
|
Re-hospitalization for Valvular Heart Disease (Judged by the physician) after discharge, divided into yes or no
|
Within a year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Ju-Chi Liu, PHD, MD, Taipei Medical University Shuang Ho Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ShuangHoH
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Wisdom bracelet
-
Taipei Medical University Shuang Ho HospitalTaipei Medical University; Taipei Medical University Hospital; Taipei Medical... et autres collaborateursPas encore de recrutementSyndrome coronarien aigu | Angioplastie coronarienne transluminale percutanée
-
Ataturk UniversityComplétéComplications postopératoiresTurquie
-
China Medical University HospitalInconnueReflux gastro-œsophagienTaïwan
-
University of Alabama at BirminghamComplété
-
Taipei Medical UniversityInconnueÉtat lié au cancerTaïwan
-
Sheba Medical CenterInconnue
-
Rush University Medical CenterRésiliéTrouble de stress post-traumatiqueÉtats-Unis
-
University of California, San FranciscoiBeat Inc.Complété
-
Thomas Jefferson UniversityInscription sur invitationBurnout | Bien-être | Surveillance à distanceÉtats-Unis